DURHAM, N.C.--(BUSINESS WIRE)-- GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced today the poster presentation of further clinical validation data for PurIST℠, a novel RNA-expression test, in collaboration with Tempus. PurIST identifies patients with the classical subtype of pancreatic ductal adenocarcinoma (PDAC) that are likely to experience longer overall survival (OS) with standard of care (SOC) FOLFIRINOX than patients with the basal subtype of PDAC. The presentation will be made at the 8th AACR Special Conference on Pancreatic Cancer in Boston, Massachusetts, which runs from September 13-16, 2022.

Title: Purity Independent Subtyping of Tumor (PurIST): Real-world data validation of a pancreatic ductal adenocarcinoma (PDAC) gene expression classifier and its prognostic implications

First Author: Stephane Wenric, PhD, Principal Scientist, Computational Systems Biology, Tempus, Chicago, Illinois

Presenting Author: James M. Davison, PhD, Senior Translational Genomics Scientist, GeneCentric Therapeutics, Durham, NC

Session: Poster Session A Poster Number: A002 Date: September 13, 2022 Time: 7:30-9:00 PM EDT

PurIST is a laboratory developed test (LDT) validated by Tempus using a real-world dataset of advanced PDAC patients. Over 250 patients with advanced PDAC who were previously treated with SOC FOLFIRINOX or gemcitabine/nab-paclitaxel were identified in Tempus’ multimodal data library. RNA sequencing (RNAseq) was performed on either primary or metastatic tumor tissue using the CAP/CLIA-validated Tempus xT assay platform. Patients were identified as either basal or classical molecular subtype. For FOLFIRINOX-treated patients, those with a classical molecular subtype had extended survival compared to those with basal molecular subtype. Survival was similar for FOLFIRINOX and gemcitabine/nab-paclitaxel treatment regimens in basal patients, but classical patients had extended survival when treated with FOLFIRINOX.

Further details surrounding test development and validation will be presented as part of an upcoming publication.

About Pancreatic Cancer

Pancreatic cancer is one of the most common cancers worldwide, and the National Cancer Institute estimates there will be 62,210 new cases and 49,830 deaths in the U.S. in 2022. It is the third-leading cause of cancer-related deaths in the U.S. and has the highest mortality rate of all major cancers. More than 90% of pancreatic cancers are pancreatic ductal adenocarcinoma (PDAC), and the 5-year overall survival for resectable/borderline-resectable and non-resectable PDAC is approximately 20-30% and 1-3%, respectively. The average patient diagnosed with Stage IV PDAC will live for about one year after diagnosis. The three main treatments for PDAC are surgical resection (if diagnosed early), radiation therapy and chemotherapy. For resectable tumors, surgical resection is provided with curative intent, however, for non-resectable tumors, chemotherapy such as FOLFIRINOX or gemcitabine with nab-paclitaxel is often used.

About GeneCentric

GeneCentric Therapeutics, Inc. is an RNA-based genomic solutions provider based in Durham, North Carolina. The company designed its technologies to parse the complexity of tumor and immune biology using its RNA-based Tumor and Immune Micro-Environment (rT(I)ME) Explorer platform to discover and develop signatures of responder populations to oncology therapeutics. GeneCentric commercializes its technology through strategic collaborations with pharmaceutical, biotechnology and diagnostics companies in applications throughout preclinical testing, clinical drug development and commercialization lifecycle phases. For more information, visit www.genecentric.com or follow us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005189/en/

Robin Fastenau [email protected]

Source: GeneCentric Therapeutics